Christine Soliman
Family Medicine · Hawthorne, CANPI 1821404450
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,344 of the $129,912 with a category attached, or 99.6%. Life Technologies Corporation accounts for 99.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $129,344 and has fallen 99.9% since, to $124 in 2023. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $12,991 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Life Technologies Corporation$129K
- Biohaven Pharmaceutical Holding Company Ltd.$433
- AbbVie$124
- AstraZeneca$11
Across 1,186 payments — averaging $1445.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Molecular Systems, Inc.$662K
- BD$264K
- Sekisui Diagnostics LLC$260K
- Roche Diagnostics Operations, Inc.$171K
- Biohaven Pharmaceutical Holding Company Ltd.$141K
- Novo Nordisk AS$119K
- plus $97K from 3 others
What the payments were for
- Speaking & faculty fees$129,344100%
- Travel & lodging$2060%
- Food & beverage$3610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Life Technologies Corporation | 4 | $129,344 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $433 |
| AbbVie | 1 | $124 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$308
- VRAYLAR$124
How this compares
$129,912 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 40 | $43,458 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $22,164 |
| JardianceEmpagliflozin | 13 | $18,295 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 45 | $18,025 |
| TrulicityDulaglutide | 11 | $17,107 |
| EliquisApixaban | 17 | $14,228 |
| LinzessLinaclotide | 24 | $13,902 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,978 |
| Icosapent Ethyl | 18 | $4,471 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $4,227 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,704 |
| Atorvastatin Calcium | 245 | $1,795 |
| Admelog SolostarInsulin Lispro | 11 | $1,711 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,552 |
| Benazepril Hcl | 138 | $1,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $124 | $13,90224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Hawthorne
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.